fbpx
CAS Insight

molecules of the month

ulotaront

TAAR1 GPCR agonist

phase III candidate for schizophrenia

from in vivo phenotypic screening

ACS Medicinal Chemistry Letters

Sunovion Pharmaceuticals, Marlborough, MA

Chemical structure of molecule Ulotaront (SEP-363856)
2 mins read

Ulotaront (SEP-363856) is a Phase III candidate with FDA Breakthrough Therapy Designation for the treatment of schizophrenia with demonstrated efficacy based on a physician-rated scale (PANSS) in a 4-week placebo-controlled trial and continued improvement in an open-label extension study. Reviewer Jake Schwarz says, “ulotaront was developed in collaboration with Psychogenics using their SmartCube® [high-throughput phenotypic screening] technology. By way of background, Psychogenics characterized all marketed CNS drugs using a (proprietary) variety of stimuli in rodents and leveraged machine learning to develop a ‘fingerprint’ for each drug. Many companies partner with Psychogenics to get a sense of what conditions their novel MOA drugs might be able to treat. That ulotaront continues to progress is great news for patients with schizophrenia, as…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: